Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-07-19
2009-06-30
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S464000, C514S469000, C514S640000, C514S646000, C514S649000, C514S730000, C702S019000, C703S011000
Reexamination Certificate
active
07553834
ABSTRACT:
A method for determining the appropriate medication for a patient suffering from depression. A patient will take a questionnaire wherein the patient answers a number of questions with scaled responses concerning the degree to which the patient's mental state is affected by at least one or both of impaired modulation and impaired activation. Next, the patient's answers will be processed to arrive at scores for the at least one impaired modulation and impaired activation. Depending upon the patient's scores for demodulation and deactivation, at least one medication which affects the at least one impaired modulation and impaired activation is recommended.
REFERENCES:
patent: 5882203 (1999-03-01), Correa et al.
Metzner R. “TTDI System Background”. [Online], 2007 [Retrieved on Sep. 5, 2007]. Retrieved from the Internet: <URL:http://ttdi.info.TTDISite/id1.html>.
Metzner R. “An Introduction to the TTDI”. [Online], 2007 [Retrieved on Sep. 5, 2007]. Retrieved from the Internet: <URL:http://www.ttdi.info>.
Metzner R. “TTDI Questionnaire”. [Online], 2007 [Retrieved on Sep. 5, 2007]. Retrieved from the Internet: <URL:http://www.ttdi.info>.
Metzner R. “Using the TTDI System”. [Online], 2008 [Retrieved on Sep. 5, 2007]. Retrieved from the Interent: <URL:http://www.ttdi.info>.
Dalery, J. et al., “Agitated-anxious versus blunted-retarded major depressions: different clinical effects of fluoxetine,” L'Encephale, 1995, 217-225, vol. XXI.
Filteau, M.J. et al., “SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients,” International Clinical Psychopharmacology, 1995, 51-54, vol. 10.
Clerc, G.E., et al. “A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia,” International Clinical Psychopharmacology, 1994, 139-143, vol. 9.
Davidson, J.R.T. et al., “The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder,” International Clinical Psychopharmacology, 1997, 41-45,vol. 12.
Heninger, G.R., et al., “The Revised Monoamine Theory of Depression: A Modulatory Role for Monoamines, Based on New Findings from Monoamine Depletion Experiments in Humans,” Pharmacopsychiat, 1996, 2-11, vol. 29.
Opbroek, A, et al., “Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?,” International Journal of Neuropsychopharmacology, 2002, 147-151, vol. 5, CINP, Cleveland, Ohio.
Zung, William W.K., “A Self-Rating Depression Scale,” Archives of General Psychiatry, Jan. 1965, 63-70, vol. 12.
Hamilton, Max, “A Rating Scale for Depression,” J. Neurol. Neurosurg. Psychiat., 1960, 56-62, vol. 23.
Beck, A.T. et al., “An Inventory for Measuring Depression,” Archives of General Psychiatry, Jun. 1961, 53-63, vol. 4.
Swartz, Conrad M., et al., “Melancholia with Onset During Treatment with SSRIs”, Annals of Clinical Psychiatry, Nov. 4, 1998, 177-179, vol. 10.
Rampello, L., et al. “Comparative Effects of Amitriptyline and Amineptine in Patients Affected by Anxious Depression,” Neuropsychobiology, 1995, 130-134, vol. 31.
Andiné, P., et al., “Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities” 1997, 82-83, vol. 96, Acta Psychiatrica Scandinavica.
Barr, Linda C. et al., “Addition of Desipramine to Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder,” American Journal of Psychiatry, Sep. 1997, 1293-1295, vol. 154:9.
Pearlstein, Teri B. et al., “Comparison of Fluoxetine, Bupropion, and Placebo in the Treatment of Premenstrual Dysphoric Disorder,” Journal of Clinical Psychopharmacology, 1997, 261-266, vol. 17, No. 4.
Stahl, Stephen, “Mixed Depression and Anxiety: Serotonin1AReceptors as a Common Pharmacologic Link,” J Clinical Psychiatry, 1997, 20-26, vol. 58 (suppl 8).
Andrews, William et al., “The SSRI antidepressants: Exploring their “other” possible properties” Journal of Affective Disorders, 1998, 141-144, vol. 49, Elsevier Science B.V.
Kaye, Walter et al., “Serotonin Neuronal Function and Selective Serotonin Reuptake Inhibitor Treatment in Anorexia and Bulimia Nervosa” Society of Biological Psychiatry, 1998, 825-838, vol. 44.
Kyle, C.J. et al., “Comparison of the Tolerability and Efficacy of Citalopram and Amitriptyline in Elderly Depressed Patients Treated in General Practice,” Depression and Anxiety, 1998, 147-153, vol. 8, Wiley-Liss, Inc.
Lydiard, R. Bruce, “The Role of Drug Therapy in Social Phobia,” Journal of Affective Disorders, 1998, vol. 50, S35-S39, Elsevier Science B.V.
Uzunova, V., et al. “Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine,,” Mar. 1998, 3239-3244, vol. 95, The National Academy of Sciences.
Verkes, Robbert J. et al. “Reduction by Paroxetine of Suicidal Behavior in Patients with, Repeated Suicide Attempts But Not Major Depression,” American Journal of Psychiatry, Apr. 1998, 543-547, vol. 155, Issue 4.
Pigott, Teresa A. et al. “A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder,” Journal of Clinical Psychiatry, Feb. 1999, 101-106, vol. 60, Issue 2.
Rampello L., et al. “Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses,” Institutes of Neurology and Neurosurgery, University of Catania, Italy, 552-554.
Goodnick, Paul J. et al. “Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders,” Journal of Clinical Psychiatry, Jan. 1993, 13-20, vol. 54, Issue 1.
Ferguson, James et al. “Bupropion in Tricyclic Antidepressant Nonresponder with Unipolar Major Depressive Disorder,” Annals of Clinical Psychiatry, 1994, vol. 6, No. 3, 153-160.
Marin, Robert S. et al. “Apathy: A Treatable Syndrome,” Journal of Neuropsychiatry and Clinical Neurosciences, Winter 1995, vol. 7, No. 1, 23-30.
Dubini, Adriana et al. “Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning,” Journal of Psychopharmacology, 1997, vol. 11, No. 4 Supplement, S17-S23.
Montgomery, Stuart A. “Is there a role for a pure noradrenergic durg in the treatment of depression?,” European Neuropsychopharmacology, 1997, S3-S9 and S71-S73, vol. 7, Suppl. 1, Elsevier Science B.V.
Cantwell, Dennis P., “ADHD Through the Life Span: The Role of Bupropion in Treatment,” Journal of Clinical Psychiatry, 1998, 92-94, vol. 59, Suppl. 4.
Cornelius, Jack R. et al., “Fluoxetine Versus Placebo in Depressed Alcoholic Cocaine Abusers,” Psychophamacology Bulletin, 1998, 117-121, vol. 34, No. 1.
Frances, Allen J., et al., “The Expert Consensus Guidelines for Treating Depression in Bipolar Disorder,” Journal of Clinical Psychiatry, 1998, 73-79, vol. 59, Supp 4.
Massana, Juan, “Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability,” Journal of Clinical Psychiatry, 1998, 8-10, vol. 59, Supp. 14.
Amsterdam, Jay D., et al., “Clomipramine Augmentation in Treatment-Resistant Depression,” Depression and Anxiety, 1997, 84-90, vol. 5.
Charney, Dennis S., M.D., “Monoamine Dysfunction and the Pathophysiology and Treatment of Depression,” Journal of Clinical Psychiatry, 1998, 11-14, vol. 14, Supp 14.
Nelson, Craig J., “Augmentation Strategies With Serotonergic-Noradrenergic Combinations”, Journal of. Clinical Psychiatry 1998, 65-69, vol. 59, Suppl 5.
Nierenberg, Andrew A., et al.“Course and Treatment of A
Christie Parker & Hale, LLP.
Marschel Ardin
Royds Leslie A
LandOfFree
Method for the targeted treatment of depression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the targeted treatment of depression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the targeted treatment of depression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143488